Hiroomi Tada, M.D., Ph.D.

Hiroomi Tada, M.D., Ph.D.

Chief Medical OfficeratTyra Biosciences· In proxies 2022–2023

Pay in FY2023+90% from the year before · Tyra Biosciences stock +82.2% the same year

Hiroomi Tada, M.D., Ph.D. was paid $2.4M in FY2023 (Dec), up 90%. Tyra Biosciences stock rose 82.2% that year.

Pay$100 in the stock at the end of FY21 → $98
Pay is from the Summary Compensation Table of each Tyra Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Tyra BiosciencesPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +50%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?